Second FDA Breakthrough Device Designation for V-Wave

V-Wave has announced that the FDA has granted it a second Breakthrough Device Designation—the first was for its interatrial shunt for heart failure and the second is for pulmonary arterial hypertension. The company is testing a minimally invasive, implanted interatrial shunt device for pulmonary artery hypertension in a global approved investigational device exemption (IDE) [...]

2019-09-17T15:30:21+00:00September 16th, 2019|Tags: , |

FDA Breakthrough Device Designation for Interarterial shunt

V-Wave has announced that the FDA has just granted the company a Breakthrough Device Designation for its interatrial shunt for heart failure. V-Wave’s minimally invasive, implanted interatrial shunt is being evaluated in a global, randomised, controlled, double-blinded, 500 patient pivotal IDE trial called RELIEVE-HF. The study is enrolling advanced heart failure patients with preserved [...]

2019-08-21T14:52:40+00:00August 21st, 2019|Tags: , , |
Go to Top